.jpg)
Our History
Combining decades of experience in the pharmaceutical, medical devices, and biotechnology industries, we identified a critical gap in specialized services for startups in Brazil. Despite the abundance of innovative ideas and disruptive potential in the country, many of these startups lack the structure, strategy, and partners needed to thrive sustainably and strategically.
Faced with this reality, we created the Brazilian Health Innovation Institute - IBIS, with the goal of providing the expertise and support needed for emerging companies in the health and biotechnology sector to develop transformative solutions and integrate into the world's leading innovation ecosystems.
The motivation behind IBIS is clear: to support health startups that need a bridge between science and the market, offering solutions that combine innovation with access to technology hubs, strategic partnerships, and business development.
Through a practical and results-oriented approach, IBIS aims to be the essential partner to help these companies grow and stand out internationally.
IBIS: Connecting History, Health & Innovation
The ibis, the bird that gives its name to the Brazilian Institute of Health Innovation, is a creature that carries deep and symbolic meanings across cultures and eras. Since the times of ancient Egypt, where it was revered as the symbol of knowledge, wisdom and healing, the ibis has represented the search for a deeper understanding of the world around us. In Egyptian mythology, it was considered the guardian of writing, science and wisdom, reflecting the ability to transform knowledge into progress.
This symbolism directly reflects IBIS’s intentions as an institute. Just like the bird, our goal is to be a bridge between deep knowledge and practical innovation, connecting science, technology and health. The ibis is also a bird with a global reach, present in various parts of the world, a characteristic that inspires us to think beyond borders, expanding the ecosystem of health innovation in Brazil and internationally.
While global reach is an essential part of our vision, IBIS also carries its brand with a Brazilian touch, through its colors and its very name. We are deeply committed to strengthening the healthcare innovation ecosystem in Brazil, recognizing the enormous potential of our startups, scientists and entrepreneurs. Brazil is a country of rich biodiversity and with a growing presence in the global biotechnology and healthcare scenario. At IBIS, we are determined to be a protagonist in this movement, connecting our local talent with international opportunities, and bringing innovative solutions within and beyond our borders.
In nature, ibis is known for its ability to navigate and adapt to different environments, always seeking new opportunities. Thus, IBIS also navigates the vast ecosystem of health and biotechnology, identifying new technologies, connecting startups, corporations and investors, and facilitating the creation of solutions that will shape the future of health in Brazil and the world.
%20(4).jpg)
Our Leadership
Marcio de Paula
Marcio de Paula has over 20 years of experience in innovation, healthcare and strategic management consulting. Recognized for his leadership in creating innovation networks and developing ecosystems focused on the biotechnology and healthcare sector, Marcio has actively contributed to the growth of startups and deeptechs in Brazil and internationally.
His work includes the founding of the Brazilian Pharmaceutical Innovation Network - RBIF and strategic roles in several initiatives in the pharmaceutical and innovation sector.
Throughout his career, Marcio has led innovative projects in both the private and public sectors, connecting companies, startups and institutions in an effort to transform science into viable commercial solutions.
Marcio is a member of the Advisory Boards of the Global Center for Risk and Innovation - GCRI (Toronto) and the Einstein Center of Competence in Advanced Therapies - Embrapii, in addition to being a strategic advisor to the Venture Capital fund Green Rock and an advisor (ad hoc) to FAPESP, where he contributes with his experience to drive technological innovation in the health sector.
Marcio is a veterinarian with a diverse and robust academic production, including executive training in innovation from the MIT Sloan School of Management, a Master's in Business Administration from Insper, an International MBA in Strategic Project Management from Fundação Getúlio Vargas with an extension at George Washington University.
Leandro Nery
Leandro Nery has a degree in Pharmacy from the University of Uberaba and specializes in the pharmaceutical industry, to which he has dedicated himself for the last 20 years. In addition to this training, he is a Specialist in Health Law from USP and has a postgraduate degree with an MBA in Business Management from BSP and is currently studying for an MBA in Pharmaceutical Industry at FIA .
His career includes experience in Brazilian and multinational companies, having worked for industry leaders such as Hypera Pharma, EMS, Eurofarma, Aché and the Novartis Group, through its generics and biosimilars division, Sandoz.
Leandro began his career in the industry in Quality Assurance and, at a very early age, moved to the Regulatory Affairs area, being directly responsible for opening new companies, registering medicines and maintaining the product portfolio. Throughout his career, he was responsible for the approval of more than 300 registrations with ANVISA. In addition to these areas and already as an industry executive, he assumed responsibility for Project Management (PMO) and R&D (Technical Documentation).
He has extensive experience in interfacing with ANVISA and in regulatory advocacy, participating in important committees in class associations such as Sindusfarma, Acessa, Abifina and other entities representing the pharmaceutical sector.
His expertise encompasses the development, registration and launch of pharmaceutical products, with a focus on innovation and strategic management, and he is a highly recognized professional for his experience in different business environments and at ANVISA, for his qualified dialogue involving technical and regulatory issues.